Hodgkin Lymphoma

Oncology
12
Pipeline Programs
8
Companies
13
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
4
2
3
0
2
1
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

ADC
583%
Small Molecule
117%
+ 6 programs with unclassified modality

Competitive Landscape

8 companies ranked by most advanced pipeline stage

Takeda
TakedaTOKYO, Japan
3 programs
1
1
1
Brentuximab VedotinPhase 4ADC1 trial
brentuximab vedotinPhase 3ADC
BrentuximabVedotinPhase 1/2ADC1 trial
Active Trials
NCT03576378Unknown41Est. Oct 2024
NCT06831370Recruiting124Est. Mar 2028
AB
Angiocrine BioscienceCA - San Diego
2 programs
1
1
AB-205Phase 31 trial
AB-205Phase 11 trial
Active Trials
NCT03925935CompletedEst. Nov 2021
NCT05181540TerminatedEst. Jan 2025
Bristol Myers Squibb
2 programs
1
1
brentuximab vedotinPhase 2ADC
RuxolitinibPhase 1/2Small Molecule3 trials
Active Trials
NCT05665192Completed150Est. Jul 2023
NCT04817007Active Not Recruiting216Est. May 2026
NCT03681561Recruiting54Est. Jul 2027
M&
Merck & Co.RAHWAY, NJ
1 program
1
Brentuximab vedotinPhase 2ADC
DS
Daiichi SankyoChina - Shanghai
1 program
1
PLX3397Phase 21 trial
Active Trials
NCT01217229Completed20Est. Apr 2012
Teva
TevaIsrael - Petach Tikva
1 program
1
BendamustinePhase 13 trials
Active Trials
NCT03755804Active Not Recruiting232Est. Jul 2028
NCT01900509Completed16Est. May 2016
NCT00076349Completed66Est. Mar 2008
ADC Therapeutics
ADC TherapeuticsNJ - New Providence
1 program
1
Camidanlumab tesirinePhase 11 trial
Active Trials
NCT02432235CompletedEst. Oct 2019
Xencor
XencorPASADENA, CA
1 program
1
XmAb2513Phase 11 trial
Active Trials
NCT00606645CompletedEst. Apr 2010

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
TakedaBrentuximab Vedotin
Angiocrine BioscienceAB-205
TevaBendamustine
Daiichi SankyoPLX3397
TevaBendamustine
Bristol Myers SquibbRuxolitinib
Bristol Myers SquibbRuxolitinib
TakedaBrentuximabVedotin
Angiocrine BioscienceAB-205
ADC TherapeuticsCamidanlumab tesirine
TevaBendamustine
XencorXmAb2513
Bristol Myers SquibbRuxolitinib

Clinical Trials (13)

Total enrollment: 919 patients across 13 trials

NCT06831370TakedaBrentuximab Vedotin

A Study of Brentuximab Vedotin With Doxorubicin, Vinblastine and Dacarbazine in Adults With Hodgkin Lymphoma in India

Start: Aug 2024Est. completion: Mar 2028124 patients
Phase 4Recruiting
NCT05181540Angiocrine BioscienceAB-205

A Study of the Effects of AB-205 in Patients With Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation

Start: Feb 2022Est. completion: Jan 2025
Phase 3Terminated
NCT03755804TevaBendamustine

Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17

Start: Dec 2018Est. completion: Jul 2028232 patients
Phase 2Active Not Recruiting
NCT01217229Daiichi SankyoPLX3397

Safety and Efficacy Study of PLX3397 in Adults With Relapsed or Refractory Hodgkin Lymphoma

Start: Mar 2011Est. completion: Apr 201220 patients
Phase 2Completed
NCT00076349TevaBendamustine

SDX-105 in Combination With Rituxan for Patients With Relapsed Indolent or Mantle Cell Non-Hodgkin's Lymphoma (NHL)

Start: Apr 2004Est. completion: Mar 200866 patients
Phase 2Completed
NCT04817007Bristol Myers SquibbRuxolitinib

A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)

Start: Mar 2021Est. completion: May 2026216 patients
Phase 1/2Active Not Recruiting
NCT03681561Bristol Myers SquibbRuxolitinib

Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma

Start: Sep 2018Est. completion: Jul 202754 patients
Phase 1/2Recruiting
NCT03576378TakedaBrentuximabVedotin

BrEPEM-LH-22017 for Older Patients With Untreated Hodgkin Lymphoma (HL)

Start: Aug 2018Est. completion: Oct 202441 patients
Phase 1/2Unknown
NCT03925935Angiocrine BioscienceAB-205

Trial of AB-205 in Adults With Lymphoma Undergoing High-Dose Therapy and Autologous Stem Cell Transplantation

Start: May 2019Est. completion: Nov 2021
Phase 1Completed
NCT02432235ADC TherapeuticsCamidanlumab tesirine

Study of ADCT-301 in Patients With Relapsed or Refractory Hodgkin and Non-Hodgkin Lymphoma

Start: Oct 2015Est. completion: Oct 2019
Phase 1Completed
NCT01900509TevaBendamustine

Bendamustine Hydrochloride, Clofarabine, and Etoposide in Treating Younger Patients With Relapsed or Refractory Hematologic Malignancies

Start: Aug 2013Est. completion: May 201616 patients
Phase 1Completed
NCT00606645XencorXmAb2513

Safety Study of XmAb®2513 to Treat Hodgkin Lymphoma or Anaplastic Large Cell Lymphoma

Start: Dec 2007Est. completion: Apr 2010
Phase 1Completed
NCT05665192Bristol Myers SquibbRuxolitinib

A Study to Assess Real-World Patient-Reported Outcomes With Fedratinib for Myelofibrosis Post-Ruxolitinib

Start: Aug 2021Est. completion: Jul 2023150 patients
N/ACompleted

Related Jobs in Oncology

Cell Therapy Account Manager（北陸）

Gilead Sciences
Japan - Tokyo
Just now

Leo Cancer Care: Senior In-House Counsel/General Counsel

Leo Cancer Care
Middleton, Wisconsin
5h ago

Summer Intern - Computational Chemistry & Artificial Intelligence

Arvinas
Remote
7h ago

Executive Medical Director, Oncology Early Development

AbbVie
Florham Park, NJ
8h ago

Executive Medical Director, Oncology Early Development

AbbVie
South San Francisco, CA
8h ago

Executive Medical Director, Oncology Early Development

AbbVie
North Chicago, IL
8h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs — potential near-term approvals
2 actively recruiting trials targeting 919 patients
8 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)